Vumerity (Diroximel Fumarate) Patent Expiration, LOE Window & CMS Spending

Vumerity (Diroximel Fumarate) by Biogen: FDA Orange Book core substance LOE 2033-10-29, 1 AB generics, $259.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiogen
FDA Application & PathwayN211855 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-10-29
Last Listed Patent or Exclusivity Date2033-10-29
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$259.3M
2024 Medicare Part D Spend$189.8M
2024 Medicaid Spend$69.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.